GMMMG logo

NHS photos

NHS logo

GMMMG Formulary

 

Drug Specific Recommendations

spacer

Guidance

1.  General Policies/Guidance

Here you will find all general guidance issued by the main GMMMG. Please scroll to the bottom of the page to ensure all documents can be seen.

 

Documents

Document Type

Date

pdf document 879KB) 

Greater Manchester botulinum toxin commissioning policy

Policy

Feb 2018

pdf document 879KB) 

Greater Manchester Antimicrobial Guidelines

Guidance

Jan 2018

pdf document 168KB) 

GMMMG Dental Prescribing Guidelines

Guidance

Jan 2018

pdf document 533KB) 

GP guide – lnfluenza outbreak in an adult care home

Guidance

Dec 2017

pdf document 297KB) 

Engagement with the Pharmaceutical Industry

Policy

Dec 2017

pdf document 101KB) 

GMMMG Appeals Policy

Policy

Dec 2017

pdf document 204KB) 

Guidance for 7 day prescriptions

Guidance

Sep 2017

pdf document 264KB) 

GM Travel Abroad Policy

Policy

Aug 2017

pdf document (89KB) 

GMMMG Statement: Flu Vaccine Types

Statement

Dec 2016

pdf document (32KB) 

GMMMG Vitamin D statement

Guidance

Sep 2016

pdf document (619KB) 

GMMMG Declarations of interest policy

Policy

Sep 2016

 

MS Word document (320KB) 

GMMMG Declaration of interests form
 

 

 

pdf document (309KB) 

Prescribing of high cost biosimilar biological medicines

Guidance

Jul 2016

pdf document (421KB) 

Polypharmacy Guidance

Guidance

May 2016

pdf document (286KB) 

Prescribing infant formula for cow’s milk protein allergy in primary care

Guidance

May 2016

pdf document (472KB) 

Management of Red Listed drugs in primary care

Guidance

Apr 2014

 

pdf document (472KB) 

Appendix 1a TPP – System One

 

 

 

pdf document (472KB) 

Appendix 1b INPS – Vision System

 

 

 

pdf document (472KB) 

Appendix 1c EMIS – Web, PCS and LV

 

 

 

pdf document (472KB) 

Appendix 1d Microtest – Evolution

 

 

pdf document (95KB) 

High cost drugs service development guideline

Policy guidance

Oct 2013

pdf document (1711KB) 

High cost drugs business case template

Business case template

Oct 2013

pdf document (119KB) 

Third party prescription request for Continence and Stoma products

Guidance

Jan 2014

pdf document (295KB) 

GM Generic Prescribing Guidelines

Guidance

Jan 2014

pdf document (298KB) 

Gluten Free Foods

Policy

Aug 2013

pdf document (134KB) 

Ratification of Documents by GMMMG

Policy

Jun 2013

pdf document (248KB) 

Prescribing following a private consultation

Guidance

Apr 2013

pdf document (91KB) 

GM Joint Formulary

Statement

Sep 2010

pdf document (98KB) 

GM Medicines Management QIPP Plan

Statement

Aug 2010

pdf document (84KB) 

Homeopathy

Policy

Jul 2010

2.  Good Practice Guidance on Rebate Schemes

Where Pharmaceutical, Nutrition or Device companies submit their Primary Care Rebate Schemes (PCRS) for consideration using the forms below then they will be taken through the Greater Manchester Medicines Management Group’s (GMMMG) ‘Ethical Framework for Considering Rebate Applications from Pharmaceutical, Nutrition and Device Companies’ by the Shared Service Medicines Optimisation Team. The outcome of this process will be notified to GMMMG and Greater Manchester (GM) Clinical Commissioning Groups (CCG) and, where they meet the requirements of the ethical framework, information about the PCRS and contact details for the relevant company representative will be provided. Companies will be notified of the outcome as well. It will then be the responsibility of individual CCGs to consider each PCRS and approach companies directly if they wish to take part.

Companies may if they wish approach GM CCGs directly to present their PCRSs for consideration. For further information please contact Greater Manchester Shared Services team on 0161 212 5680 or  GMMMG@nhs.net

 3.  GMMMG Advisory Position for the Commissioning of PbR Excluded Drugs

These documents have been approved by GMMMG and the drugs list is a best estimate of the commissioner for PbR excluded drugs for 2017-19. The drugs list will be subject to further revision as NHS England provides further information on the drugs it commissions and when new drugs enter the market. An attempt to identify the commissioner for PbR devices has also been made. The supporting information and the lists themselves are currently being reviewed in detail under the auspices of the High Cost Drugs subgroup. Please send any comments and notice of errors or omissions to GMMMG@nhs.net

<< Back

Line

TERMS AND CONDITIONS    |    CONTACT US    |    ABOUT US    |    ARCHIVE

RSS Feed
 
spacer